Darin J. Weber Sells 17,238 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 17,238 shares of the stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $2.50, for a total transaction of $43,095.00. Following the completion of the sale, the senior vice president now directly owns 172,432 shares in the company, valued at $431,080. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

ProKidney Price Performance

Shares of NASDAQ:PROK opened at $2.04 on Friday. The business’s 50-day moving average is $1.60 and its 200 day moving average is $1.79. ProKidney Corp. has a 1 year low of $1.12 and a 1 year high of $13.51. The firm has a market capitalization of $467.85 million, a P/E ratio of -3.58 and a beta of 1.08.

ProKidney (NASDAQ:PROK) last announced its earnings results on Thursday, March 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. On average, analysts expect that ProKidney Corp. will post -0.65 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PROK. Bank of America lowered shares of ProKidney from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd. Morgan Stanley assumed coverage on ProKidney in a research report on Thursday, March 7th. They set an “equal weight” rating and a $3.00 price target on the stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PROK. Lazard Asset Management LLC acquired a new position in ProKidney during the 2nd quarter valued at about $31,000. Tower Research Capital LLC TRC increased its holdings in shares of ProKidney by 98.5% in the first quarter. Tower Research Capital LLC TRC now owns 4,456 shares of the company’s stock valued at $50,000 after purchasing an additional 2,211 shares during the period. Legal & General Group Plc acquired a new position in shares of ProKidney in the fourth quarter valued at about $57,000. Ameritas Investment Partners Inc. acquired a new position in shares of ProKidney in the second quarter valued at about $57,000. Finally, UBS Group AG increased its holdings in shares of ProKidney by 97.5% in the first quarter. UBS Group AG now owns 5,209 shares of the company’s stock valued at $59,000 after purchasing an additional 2,571 shares during the period. 51.59% of the stock is owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.